DNA methylation status of REIC/Dkk-3 gene in human malignancies

Tatsuro Hayashi, Hiroaki Asano, Shinichi Toyooka, Kazunori Tsukuda, Junichi Sou, Tadahiko Shien, Naruto Taira, Yuho Maki, Norimitsu Tanaka, Hiroyoshi Doihara, Yasutomo Nasu, Nam Ho Huh, Shinichiro Miyoshi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: The REIC (reduced expression in immortalized cells)/Dkk-3 is down-regulated in various cancers and considered to be a tumor suppressor gene. REIC/Dkk-3 mRNA has two isoforms (type-a,b). REIC type-a mRNA has shown to be a major transcript in various cancer cells, and its promoter activity was much stronger than that of type-b. In this study, we examined the methylation status of REIC/ Dkk-3 type-a in a broad range of human malignancies. Methods: We examined REIC/Dkk-3 type-a methylation in breast cancers, non-small-cell lung cancers, gastric cancers, colorectal cancers, and malignant pleural mesotheliomas using a quantitative combined bisulfite restriction analysis assay and bisulfate sequencing. REIC/Dkk-3 type-a and type-b expression was examined using reverse transcriptional PCR. The relationships between the methylation and clinicopathological factors were analyzed. Results: The rate of REIC/Dkk-3 type-a methylation ranged from 26.2 to 50.0% in the various primary tumors that were examined. REIC/Dkk-3 type-a methylation in breast cancer cells was significantly heavier than that in the other cell lines that we tested. REIC/Dkk-3 type-a methylation was inversely correlated with REIC/Dkk-3 type-a expression. There was a correlation between REIC/Dkk-3 type-a and type-b mRNA expression. REIC/Dkk-3 type-a expression was restored in MDA-MB-231 cells using 5-aza-2'-deoxycytidine treatment. We found that estrogen receptor-positive breast cancers were significantly more common among the methylated group than among the nonmethylated group. Conclusions: REIC/Dkk-3 type-a methylation was frequently detected in a broad range of cancers and appeared to play a key role in silencing REIC/Dkk-3 type-a expression in these malignancies.

Original languageEnglish
Pages (from-to)799-809
Number of pages11
JournalJournal of Cancer Research and Clinical Oncology
Volume138
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

DNA Methylation
Genes
Neoplasms
Methylation
decitabine
Breast Neoplasms
Messenger RNA
Stomach Neoplasms
Tumor Suppressor Genes
Non-Small Cell Lung Carcinoma
Estrogen Receptors

Keywords

  • Breast cancer
  • DNA methylation
  • Lung cancer
  • Mesothelioma
  • REIC/Dkk-3

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

DNA methylation status of REIC/Dkk-3 gene in human malignancies. / Hayashi, Tatsuro; Asano, Hiroaki; Toyooka, Shinichi; Tsukuda, Kazunori; Sou, Junichi; Shien, Tadahiko; Taira, Naruto; Maki, Yuho; Tanaka, Norimitsu; Doihara, Hiroyoshi; Nasu, Yasutomo; Huh, Nam Ho; Miyoshi, Shinichiro.

In: Journal of Cancer Research and Clinical Oncology, Vol. 138, No. 5, 05.2012, p. 799-809.

Research output: Contribution to journalArticle

Hayashi, Tatsuro ; Asano, Hiroaki ; Toyooka, Shinichi ; Tsukuda, Kazunori ; Sou, Junichi ; Shien, Tadahiko ; Taira, Naruto ; Maki, Yuho ; Tanaka, Norimitsu ; Doihara, Hiroyoshi ; Nasu, Yasutomo ; Huh, Nam Ho ; Miyoshi, Shinichiro. / DNA methylation status of REIC/Dkk-3 gene in human malignancies. In: Journal of Cancer Research and Clinical Oncology. 2012 ; Vol. 138, No. 5. pp. 799-809.
@article{602425f8b8754d0cb0604f924b983140,
title = "DNA methylation status of REIC/Dkk-3 gene in human malignancies",
abstract = "Purpose: The REIC (reduced expression in immortalized cells)/Dkk-3 is down-regulated in various cancers and considered to be a tumor suppressor gene. REIC/Dkk-3 mRNA has two isoforms (type-a,b). REIC type-a mRNA has shown to be a major transcript in various cancer cells, and its promoter activity was much stronger than that of type-b. In this study, we examined the methylation status of REIC/ Dkk-3 type-a in a broad range of human malignancies. Methods: We examined REIC/Dkk-3 type-a methylation in breast cancers, non-small-cell lung cancers, gastric cancers, colorectal cancers, and malignant pleural mesotheliomas using a quantitative combined bisulfite restriction analysis assay and bisulfate sequencing. REIC/Dkk-3 type-a and type-b expression was examined using reverse transcriptional PCR. The relationships between the methylation and clinicopathological factors were analyzed. Results: The rate of REIC/Dkk-3 type-a methylation ranged from 26.2 to 50.0{\%} in the various primary tumors that were examined. REIC/Dkk-3 type-a methylation in breast cancer cells was significantly heavier than that in the other cell lines that we tested. REIC/Dkk-3 type-a methylation was inversely correlated with REIC/Dkk-3 type-a expression. There was a correlation between REIC/Dkk-3 type-a and type-b mRNA expression. REIC/Dkk-3 type-a expression was restored in MDA-MB-231 cells using 5-aza-2'-deoxycytidine treatment. We found that estrogen receptor-positive breast cancers were significantly more common among the methylated group than among the nonmethylated group. Conclusions: REIC/Dkk-3 type-a methylation was frequently detected in a broad range of cancers and appeared to play a key role in silencing REIC/Dkk-3 type-a expression in these malignancies.",
keywords = "Breast cancer, DNA methylation, Lung cancer, Mesothelioma, REIC/Dkk-3",
author = "Tatsuro Hayashi and Hiroaki Asano and Shinichi Toyooka and Kazunori Tsukuda and Junichi Sou and Tadahiko Shien and Naruto Taira and Yuho Maki and Norimitsu Tanaka and Hiroyoshi Doihara and Yasutomo Nasu and Huh, {Nam Ho} and Shinichiro Miyoshi",
year = "2012",
month = "5",
doi = "10.1007/s00432-012-1158-6",
language = "English",
volume = "138",
pages = "799--809",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - DNA methylation status of REIC/Dkk-3 gene in human malignancies

AU - Hayashi, Tatsuro

AU - Asano, Hiroaki

AU - Toyooka, Shinichi

AU - Tsukuda, Kazunori

AU - Sou, Junichi

AU - Shien, Tadahiko

AU - Taira, Naruto

AU - Maki, Yuho

AU - Tanaka, Norimitsu

AU - Doihara, Hiroyoshi

AU - Nasu, Yasutomo

AU - Huh, Nam Ho

AU - Miyoshi, Shinichiro

PY - 2012/5

Y1 - 2012/5

N2 - Purpose: The REIC (reduced expression in immortalized cells)/Dkk-3 is down-regulated in various cancers and considered to be a tumor suppressor gene. REIC/Dkk-3 mRNA has two isoforms (type-a,b). REIC type-a mRNA has shown to be a major transcript in various cancer cells, and its promoter activity was much stronger than that of type-b. In this study, we examined the methylation status of REIC/ Dkk-3 type-a in a broad range of human malignancies. Methods: We examined REIC/Dkk-3 type-a methylation in breast cancers, non-small-cell lung cancers, gastric cancers, colorectal cancers, and malignant pleural mesotheliomas using a quantitative combined bisulfite restriction analysis assay and bisulfate sequencing. REIC/Dkk-3 type-a and type-b expression was examined using reverse transcriptional PCR. The relationships between the methylation and clinicopathological factors were analyzed. Results: The rate of REIC/Dkk-3 type-a methylation ranged from 26.2 to 50.0% in the various primary tumors that were examined. REIC/Dkk-3 type-a methylation in breast cancer cells was significantly heavier than that in the other cell lines that we tested. REIC/Dkk-3 type-a methylation was inversely correlated with REIC/Dkk-3 type-a expression. There was a correlation between REIC/Dkk-3 type-a and type-b mRNA expression. REIC/Dkk-3 type-a expression was restored in MDA-MB-231 cells using 5-aza-2'-deoxycytidine treatment. We found that estrogen receptor-positive breast cancers were significantly more common among the methylated group than among the nonmethylated group. Conclusions: REIC/Dkk-3 type-a methylation was frequently detected in a broad range of cancers and appeared to play a key role in silencing REIC/Dkk-3 type-a expression in these malignancies.

AB - Purpose: The REIC (reduced expression in immortalized cells)/Dkk-3 is down-regulated in various cancers and considered to be a tumor suppressor gene. REIC/Dkk-3 mRNA has two isoforms (type-a,b). REIC type-a mRNA has shown to be a major transcript in various cancer cells, and its promoter activity was much stronger than that of type-b. In this study, we examined the methylation status of REIC/ Dkk-3 type-a in a broad range of human malignancies. Methods: We examined REIC/Dkk-3 type-a methylation in breast cancers, non-small-cell lung cancers, gastric cancers, colorectal cancers, and malignant pleural mesotheliomas using a quantitative combined bisulfite restriction analysis assay and bisulfate sequencing. REIC/Dkk-3 type-a and type-b expression was examined using reverse transcriptional PCR. The relationships between the methylation and clinicopathological factors were analyzed. Results: The rate of REIC/Dkk-3 type-a methylation ranged from 26.2 to 50.0% in the various primary tumors that were examined. REIC/Dkk-3 type-a methylation in breast cancer cells was significantly heavier than that in the other cell lines that we tested. REIC/Dkk-3 type-a methylation was inversely correlated with REIC/Dkk-3 type-a expression. There was a correlation between REIC/Dkk-3 type-a and type-b mRNA expression. REIC/Dkk-3 type-a expression was restored in MDA-MB-231 cells using 5-aza-2'-deoxycytidine treatment. We found that estrogen receptor-positive breast cancers were significantly more common among the methylated group than among the nonmethylated group. Conclusions: REIC/Dkk-3 type-a methylation was frequently detected in a broad range of cancers and appeared to play a key role in silencing REIC/Dkk-3 type-a expression in these malignancies.

KW - Breast cancer

KW - DNA methylation

KW - Lung cancer

KW - Mesothelioma

KW - REIC/Dkk-3

UR - http://www.scopus.com/inward/record.url?scp=84862281500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862281500&partnerID=8YFLogxK

U2 - 10.1007/s00432-012-1158-6

DO - 10.1007/s00432-012-1158-6

M3 - Article

VL - 138

SP - 799

EP - 809

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 5

ER -